Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of oral AMT-101 in rheumatoid arthritis with inadequate response to anti-TNF therapy
2020-003955-14Phase 2Terminated
- Sponsor
- Applied Molecular Transport
- Start
- Nov 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing AMT-101 once daily with Placebo once daily (2 arms). Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 1 more. Started Nov 2020; status: terminated.
02
Drugs
AMT-101
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2020-003955-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003955-14.